Jilin Changlong Bio Pharmacy SEHK 8049 Margin Strength Reinforces Bullish Valuation Narratives

Jilin Province Huinan Changlong Bio-pharmacy (SEHK:8049) has posted its FY 2025 first half results with revenue of C¥438.9 million and basic EPS of C¥0.184, set against trailing 12 month revenue of C¥901.9 million and EPS of C¥0.355 that came alongside a 7.9% earnings uplift and net profit margins of 22.1%. Over the past year, the company has seen revenue move between C¥881.2 million and C¥926.9 million on a trailing 12 month basis, with basic EPS ranging from C¥0.327 to C¥0.355. This gives a clear view of how the top line and per share profitability have tracked into this latest release. With margins holding in the low 20% range and earnings growth already reported, the fresh numbers land in a context where profitability trends are front and center for investors.

See our full analysis for Jilin Province Huinan Changlong Bio-pharmacy.

With the headline figures set, the next step is to see how these results line up with the widely held narratives around the business, and where the numbers may challenge what the market has come to expect.

Curious how numbers become stories that shape markets? Explore Community Narratives

TTM net profit of C¥198.9 million supports 22.1% margin story

• On a trailing 12 month view, net income excluding extra items sits at C¥198.9 million on C¥901.9 million of revenue, lining up with the 22.1% net profit margin that investors have been using as a key reference point.
• What stands out for a cautiously bullish view is that this margin sits alongside 7.9% trailing earnings growth and a five year earnings growth rate of 6.7% per year, which supports the idea of a steady, profitable business, yet
  • the latest half year net income figures move between C¥103.0 million and C¥104.3 million over the last three half year periods, so the bullish case rests more on consistency than on rapid acceleration,
  • and anyone leaning bearish on growth can point to this tight range as a sign that recent profitability has been relatively stable rather than sharply higher.

Results like these often split opinion, and the most useful conversations tend to come from seeing how other investors connect the numbers to their long term stories for the company, which you can do through the 📊 Read the what the Community is saying about Jilin Province Huinan Changlong Bio-pharmacy.

TTM P/E of 5.8x sits far below 15.6x industry level

• The shares trade on a trailing P/E of 5.8x compared with 14.6x for peers and 15.6x for the wider Hong Kong Pharmaceuticals industry, even though the same trailing period produced a 22.1% net margin and C¥0.355 in EPS.
• For investors weighing a bullish argument that the stock is being priced too low, the combination of a low P/E and the reported profitability strongly feeds that view, while
  • bears can still argue that the low multiple reflects concerns that past earnings, even with a 7.9% trailing increase, may not be enough on their own to change how the market values the company,
  • so the valuation gap becomes a central debate point rather than a one sided win for either camp.

Share price C$2.33 versus DCF fair value of HK$14.23

• The current share price of HK$2.33 sits well below the stated DCF fair value of HK$14.23, a gap of 83.6% that sits on top of the already low 5.8x trailing P/E and the 22.1% net margin.
• Supporters of a bullish narrative see this spread as a sign the market could be overlooking the company’s high quality past earnings, yet
  • income focused investors may balance that view with the comment that the dividend track record is unstable, which keeps the story more about valuation and profitability than about regular cash returns,
  • and skeptics can reasonably ask whether the DCF assumptions fully align with the recent pattern of revenue moving between C¥881.2 million and C¥926.9 million on a trailing 12 month basis.

Next Steps

Don't just look at this quarter; the real story is in the long-term trend. We've done an in-depth analysis on Jilin Province Huinan Changlong Bio-pharmacy's growth and its valuation to see if today's price is a bargain. Add the company to your watchlist or portfolio now so you don't miss the next big move.

Mixed signals or a clear story taking shape, either way this is a moment to check the data for yourself and move quickly. To see where the balance lies between concern and optimism, review the 2 key rewards and 1 important warning sign

See What Else Is Out There

The company’s tight earnings range, valuation debate and unstable dividend track record leave questions about how dependable its cash returns might be for income seekers.

If you want income that feels more dependable, check out 454 dividend fortresses today and quickly compare companies built around stronger and more consistent dividend profiles.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com